Is It Too Late To Consider Olema Pharmaceuticals (OLMA) After Its 320% One-Year Surge?

Simply Wall St.

Jan 31

If you are wondering whether Olema Pharmaceuticals is still priced attractively after its recent run, this article walks through the numbers in a clear, valuation focused way. The stock recently ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2608072486"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608072486\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608072486?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-01-31 21:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608072486","market":"us","top_or_hot":-1,"title":"Is It Too Late To Consider Olema Pharmaceuticals (OLMA) After Its 320% One-Year Surge?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Olema Pharmaceuticals is still priced attractively after its recent run, this article walks through the numbers in a clear, valuation focused way. The stock recently ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-olma/olema-pharmaceuticals/news/is-it-too-late-to-consider-olema-pharmaceuticals-olma-after\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Too Late To Consider Olema Pharmaceuticals (OLMA) After Its 320% One-Year Surge?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Too Late To Consider Olema Pharmaceuticals (OLMA) After Its 320% One-Year Surge?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-31 21:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-olma/olema-pharmaceuticals/news/is-it-too-late-to-consider-olema-pharmaceuticals-olma-after><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Olema Pharmaceuticals is still priced attractively after its recent run, this article walks through the numbers in a clear, valuation focused way. The stock recently ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-olma/olema-pharmaceuticals/news/is-it-too-late-to-consider-olema-pharmaceuticals-olma-after\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-olma/olema-pharmaceuticals/news/is-it-too-late-to-consider-olema-pharmaceuticals-olma-after","article_id":"2608072486","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-olma/olema-pharmaceuticals/news/is-it-too-late-to-consider-olema-pharmaceuticals-olma-after","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608072486","pubTimestamp":1769865855,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Olema Pharmaceuticals is still priced attractively after its recent run, this article walks through the numbers in a clear, valuation focused way.\nThe stock recently closed at US$25.72, with returns of 1.9% over 7 days, 2.9% over 30 days, 1.7% year to date and 320.9% over the past year, while the 3 year return sits at 465.3% and the 5 year return at a 45.7% decline.\nRecent attention on Olema has centered on its position in the pharmaceuticals and biotech space...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","OLMA":"Olema Pharmaceuticals, Inc.","BK4505":"高瓴资本持仓","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"Olema Pharmaceuticals(OLMA)一年飙升320%后，现在考虑是否为时已晚？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"OLMA":1.5},"content_text":"If you are wondering whether Olema Pharmaceuticals is still priced attractively after its recent run, this article walks through the numbers in a clear, valuation focused way. The stock recently closed at US$25.72, with returns of 1.9% over 7 days, 2.9% over 30 days, 1.7% year to date and 320.9% over the past year, while the 3 year return sits at 465.3% and the 5 year return at a 45.7% decline. Recent attention on Olema has centered on its position in the pharmaceuticals and biotech space and how its share price performance compares with peers and broader sector trends. This context helps frame whether the recent move toward US$25.72 reflects changing expectations about its prospects or simply a reset after earlier swings. Olema currently scores 3 out of 6 on our valuation checks, meaning it screens as undervalued on half of the metrics we track. You can see the breakdown in our valuation score. Next, we will walk through the main valuation approaches investors often rely on for a stock like this and then finish with a more complete way to think about value.  Olema Pharmaceuticals delivered 320.9% returns over the last year. See how this stacks up to the rest of the Biotechs industry. AdvertisementApproach 1: Olema Pharmaceuticals Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model takes expected future cash flows and discounts them back to today to estimate what the whole business might be worth in dollars right now. It is essentially asking what those future dollars are worth in present terms. For Olema Pharmaceuticals, the model used is a 2 stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of $134.673 million, and analyst projections, combined with Simply Wall St extrapolations, indicate free cash flow of $52.133 million by 2030. The ten year path includes several years of forecast cash outflows before turning positive, which is common for early stage biotechs. When all those projected cash flows are discounted back to today, the DCF model produces an intrinsic value estimate of about $30.42 per share, compared with the recent price of $25.72. That difference equates to an implied 15.5% discount, which indicates Olema is trading below this particular estimate of fair value. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Olema Pharmaceuticals is undervalued by 15.5%. Track this in your watchlist or portfolio, or discover 868 more undervalued stocks based on cash flows. OLMA Discounted Cash Flow as at Jan 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Olema Pharmaceuticals. Approach 2: Olema Pharmaceuticals Price vs Book For companies that are still loss making, earnings based multiples are less useful, so investors often look at price relative to the balance sheet instead. The P/B ratio compares the share price with the accounting value of net assets, which can be a practical anchor for early stage biotechs. What counts as a \"normal\" P/B ratio depends on what the market is pricing in for future growth and how risky those expectations appear. Higher expected growth or lower perceived risk can justify a higher P/B, while more uncertainty or weaker prospects usually point to a lower figure. Olema trades on a P/B of 6.58x, compared with the Biotechs industry average of 2.59x and a peer group average of 8.75x. Simply Wall St also uses a proprietary \"Fair Ratio\" for P/B, which estimates the multiple that might make sense based on factors like growth outlook, margins, risk profile, market value and industry. This can be more tailored than a simple peer or sector comparison, because it looks at company specific characteristics rather than broad groupings. On this framework, Olema’s current 6.58x P/B sits above the industry average and below peers, and the Fair Ratio helps clarify whether that premium is supported by its fundamentals or not. Result: ABOUT RIGHT NasdaqGS:OLMA P/B Ratio as at Jan 2026 P/B ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1417 companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your Olema Pharmaceuticals Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple way to connect your view of Olema Pharmaceuticals with the numbers behind it. A Narrative is your story for the company, where you spell out what you think could happen to revenue, earnings and margins, then link that to an assumed fair value instead of relying on a single model or ratio. On Simply Wall St, within the Community page used by millions of investors, Narratives make this easier by tying a company’s story to a clear financial forecast and a fair value estimate. You can then compare this directly with the current share price to help you decide whether you prefer to buy, hold or sell. Because Narratives update when new information such as news or earnings is added to the platform, your fair value view can stay aligned with what is happening. For Olema, you might see one investor using very optimistic revenue and margin assumptions and another using more cautious inputs, leading to very different fair value ranges even though they are looking at the same stock price. Do you think there's more to the story for Olema Pharmaceuticals? Head over to our Community to see what others are saying! NasdaqGS:OLMA 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}